[ biotech news ] Molecular Profiling Institute Secures $7.5 million in Series B Funding

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

Molecular Profiling Institute Secures $7.5 million in Series B
Funding; AmeriPath, Affymetrix, and Gen-Probe Provide Funding to
Accelerate the Introduction of New Genetic-Based Prognostics to
Cancer Patients

PHOENIX ARIZONA Oct. 28, 2005 The Molecular Profiling Institute,
Inc. (Molecular Profiling) today announced that it has secured $7.5
million in capital through a Series B financing from three key
investors: AmeriPath, Affymetrix and Gen-Probe Incorporated.
Molecular Profiling is a leading specialty reference laboratory that
utilizes proprietary genomic analysis methods to guide treatment
decisions for cancer patients.

"Our series B funding will accelerate the introduction of our new
genetic-based profiling to oncology patients," said Dr. Robert J.
Penny, Molecular Profiling President and CEO.

The funding will be utilized to launch additional molecular tests in
the areas of breast cancer, prostate cancer, and lymphoma and to
develop additional assays through collaborations in clinical trials
that indicate populations of patients who may best respond to
targeted cancer therapies. Among the testing offered, Molecular
Profiling has an exclusive license to provide the MammaPrint(R) 70
gene breast cancer prognostic in the United States and also provides
tissue banking and analysis services for a number of pharmaceutical
organizations.

Molecular Profiling's advanced tests are provided principally
through their partner AmeriPath, one of the leading anatomic
pathology laboratory companies in the United States. "Following
AmeriPath's planned acquisition of Specialty Laboratories, an
enhanced role in Molecular Profiling enables us to better provide
the latest and best testing for cancer patients to a wider patient
base," said Keith Laughman, President for Esoteric Services at
AmeriPath. "Molecular Profiling gives us unique access to a top
genetic testing laboratory and a pipeline to unique proprietary
testing, which is important to our pathologists as we deliver
premier healthcare to the communities and the patients that we
serve."

Robert Lipshutz, Ph.D., Senior Vice President, Emerging Markets and
Molecular Diagnostics at Affymetrix stated that "We are pleased to
be working with Molecular Profiling to accelerate scientific
breakthroughs that will help improve patient care." Affymetrix'
GeneChip technology enables researchers to identify and measure
genes that are similarly expressed among a group of people who share
the same disease.

Gen-Probe, which manufactures a broad portfolio of diagnostic and
blood screening products to detect a variety of diseases, has also
established a collaboration with Molecular Profiling to validate and
commercialize certain of its investigational assays. The first will
be the investigational PCA3 test, which is intended as an aid in the
diagnosis of prostate cancer. Henry L. Nordhoff, Chairman, President
and CEO of Gen-Probe stated that "Molecular Profiling has the
capability to facilitate our product validation and market entry."

Molecular Profiling was founded as the conduit for the commercial
application of the Translational Genomics Research Institute's
(TGen) research projects and the International Genomics Consortium's
(IGC) tissue banking and analysis capabilities.

About the Molecular Profiling Institute Inc. - Molecular Profiling
is a CLIA-certified specialty reference laboratory that helps cancer
patients worldwide by applying the discoveries of the Human Genome
Project to personalized medicine. Molecular Profiling provides
cutting-edge testing facilities, products, and resources for genomic
and proteomic profiling and treatment of cancers and pharmaceutical
services to identify populations that may respond to targeted
therapies. Molecular Profiling has strategic relationships with
AmeriPath Inc., Affymetrix Inc., Gen-Probe Inc., IBM, the
International Genomics Consortium (IGC), and the Translational
Genomics Research Institute (TGen). For more information, please see
www.molecularprofiling.com.

About Affymetrix - Affymetrix scientists invented the world's first
microarray in 1989 and began selling the first commercial microarray
in 1994. Since then, Affymetrix GeneChip(R) technology has become
the industry standard in molecular biology research. Affymetrix
technology is used by the world's top pharmaceutical, diagnostic and
biotechnology companies as well as leading academic, government and
not-for-profit research institutes. More than 1,300 systems have
been shipped around the world and more than 3,000 peer-reviewed
papers have been published using the technology. Affymetrix'
patented photolithographic manufacturing process provides the most
information capacity available today on an array, enabling
researchers to use a whole-genome approach to analyze the
relationship between genetics and health. Headquartered in Santa
Clara, Calif., Affymetrix has subsidiaries in Europe and Asia in
addition to manufacturing facilities in Sacramento, Calif. and
Bedford, Mass. The company has about 1000 employees worldwide. For
more information, please see www.affymetrix.com.

About AmeriPath Inc. - AmeriPath is one of the leading anatomic
pathology laboratory companies in the United States. AmeriPath
offers a broad range of testing and information services used by
physicians in the detection, diagnosis, evaluation and treatment of
cancer and other diseases and medical conditions. The company's
extensive diagnostics infrastructure includes over 400 pathologists
and doctorate-level scientists providing services in over 20 states
utilizing 40 independent pathology laboratories, more than 200
hospitals, and their Centers of Excellence. For more information,
please see www.ameripath.com.

About Gen-Probe - Gen-Probe Incorporated is a global leader in the
development, manufacture and marketing of rapid, accurate and cost-
effective nucleic acid tests (NATs) used to diagnose human diseases
and screen donated human blood. Gen-Probe markets a broad portfolio
of products that use the Company's patented technologies to detect
infectious microorganisms, including those causing sexually
transmitted diseases, tuberculosis, strep throat, pneumonia and
fungal infections. The Company also developed and manufactures the
only FDA-approved blood-screening assay for the simultaneous
detection of HIV-1 and HCV, which is marketed by Chiron Corporation.
In addition, Gen-Probe's TIGRIS instrument is the only fully
automated, high-throughput NAT system for diagnostics and blood
screening. For more information, please see www.gen-probe.com.

About the International Genomics Consortium (IGC) - IGC is a non-
profit medical research foundation established to serve common,
unmet needs including: the standardization of the collection of
properly consented tissues of interest, the molecular
characterization of these tissues, and standardization in the
representation of these results. For more information, please see
www.intgen.org.

About the Translational Genomics Research Institute (TGen) - TGen's
mission is to make and translate genomic discoveries into advances
in human health. "Translational research" is a relatively new field
employing innovative advances, such as genome-wide array technology,
and the burgeoning field of computational biology, to provide the
data and tools necessary to identify the genes that play a role in
hereditary susceptibility to disease. For more information, please
see www.tgen.org.

http://groups.yahoo.com/group/biotech-news/
http://www.azhttp.com/

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] The Top Biotechnology Companies are Expected to Continue Outpacing the Overall

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

The Top Biotechnology Companies are Expected to Continue Outpacing
the Overall Growth of the Pharmaceutical Market in the Next 5 Years

http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/

Research and Markets
(researchandmarkets.com/reports/c26643) has announced the addition
of The Top 10 Biotechnology Companies to their offering.

The top biotechnology companies are expected to continue
outpacing the
overall growth of the pharmaceutical market in the next 5 years, and
prospects for long-term success have never been greater. The leading
biotechnology companies are evolving into integrated companies,
retaining
ownership of their developmental compounds and building in-house
sales and
marketing functions.
'The Top 10 Biotechnology Companies' is a new management report
which
provides a detailed analysis of the 10 leading biotechnology
companies and
how they are planning to sustain growth over the next five years.
For each
company this report analyzes current and future therapeutic focus,
sales
growth, key pipeline products and how they are positioned for future
growth.
The Top Ten Biotechnology Companies analyzed in this report are:

1. Amgen
2. Genentech
3. Serono
4. Biogen Idec
5. UCB-Celltech
6. Genzyme
7. Gilead
8. MedImmune
9. Chiron
10. Millennium

This new report will help you to identify the critical success
factors
that have driven company growth, evaluate diversification
opportunities and
assess the future potential of each company's R&D portfolio over the
next
five years.
Key questions answered in this report
- What market shares do the top 10 biotechs hold in the global
biotechnology market?
- What are the major strengths, weaknesses, opportunities and
threats for
the top 10?
- Which companies in the top 10 are growing the fastest, and
which are
performing worst and why?
- What are the main problems encountered by biotechs on their
way to
achieving growth and profitability?
- Which companies are most active in licensing and alliance
activity, and
are these licensing/alliances with large pharmaceutical firms or
with small
biotech players?
- Which of the top 10 biotechs have the most promising drug
pipelines for
the future?
Reasons to read this report
- Tailor the best practice strategies of the biotech industry's
global
giants, to your company's needs, by reviewing detailed profiles of
current
and future drug portfolio's, growth strategies and organizational
structure.
- Assess the pipeline strength of the top 10 biotechs companies
and
identify possible in-licensing or out-licensing opportunities.
- Turn your competitor's weaknesses into your strengths and gain
a
competitive edge through in-depth analysis the top 10 companies.
- Understand how the strategies of the leading integrated
biotechs differ
from emerging top-tier biotechs and identify the critical success
factors for
both types of strategies
- Identify which therapy areas offer the greatest opportunity
for your
company by evaluating the therapeutic focus of your competitors.
For more information visit

researchandmarkets.com/reports/c26643

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Pancreatic Cancer Screensaver Lifesaver Program Identifies New Therapeutic Compo

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

Pancreatic Cancer Screensaver Lifesaver Program Identifies New
Therapeutic Compounds

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/

Millions of home computers link together to accelerate the drug
discovery process

10-26-2005

Phoenix, AZ, October 25, 2005-After just five months of operation,
the Pancreatic Cancer Screensaver Lifesaver program has identified
two compounds that show promise against pancreatic cancer. The
worldwide Screensaver Lifesaver program links together millions of
home computers with access to the Internet to help discover new
pancreatic cancer drugs by running a special screensaver when it's
idle. The Pancreatic Cancer Screensaver program was announced in
April 2005 by the National Foundation for Cancer Research (NFCR) led
by Franklin C. Salisbury, Jr., Dr. Graham Richards, Chairman of the
Oxford University Chemistry Department and Dr. Daniel Von Hoff,
Director of the NFCR Center for Targeted Cancer Therapies at the
University of Arizona in Tucson and the Translational Genomics
Research Institute (TGen).
"The outcome of this project is absolutely remarkable," said
Franklin C. Salisbury, Jr., president of the NFCR. "The computing
power of the Screensaver program is essential to accelerating the
search for new cancer therapies."

The program uses parallel computing power to assess the interactions
between small drug-like molecules and predetermined cancer-causing
targets, shaving up to three years off the drug discovery process.

The screensaver program includes a drug-design software application
that can be downloaded at www.grid.org. Each subscribing computer
receives an initial bundle of 100 molecules and a model of a target
protein. The program calculates the binding energy between the small
molecules and the targets. Typically a day later, after processing
is complete, the program sends the results back to a data center and
requests more molecules.

The pancreatic program has been running to identify compounds that
hit several newly identified protein targets in pancreatic cancer
(primarily kinases and phosphatases). After just five months, a
total of 917 potential chemical hits were identified and two
compounds in particular show promise in fighting pancreatic cancer.
The next step is to further perfect these compounds and bring them
into a clinical trial as soon as possible.

"This Lifesaver-Screensaver project targeting pancreatic cancer will
work to speed the drug development process by at least 3 years,
hopefully more," said Dr. Von Hoff, director of TGen's Translational
Drug Development Division.

The results from the Pancreatic Cancer Screensaver Lifesaver program
will be presented by TGen's Dr. Haiyong Han at an international
molecular targets meeting next month in Philadelphia.

# # #

About TGen
The mission of the Translational Genomics Research Institute (TGen)
is to make and translate genomic discoveries into advances in human
health. Translational genomics research is a relatively new field
employing innovative advances arising from the Human Genome Project
and applying them to the development of diagnostics, prognostics and
therapies for cancer, neurological disorders, diabetes and other
complex diseases. TGen is focused on personalized medicine and plans
to accomplish its goals through robust and disease-focused research.

About the National Foundation for Cancer Research (NFCR)
Since its founding, the NFCR has spent more than $218 million
funding basic science cancer research and prevention education
focused on understanding how and why cells become cancerous. NFCR is
dedicated to funding scientists who are discovering cancer's
molecular mysteries and translating these discoveries into therapies
that hold the hope for curing cancer. For more information visit
www.NFCR.org or call (800) 321-CURE.

About Oxford University
The University of Oxford is internationally renowned for the quality
and diversity of its research, with over 3000 academic staff and
3000 postgraduate students working on research. The Chemistry
Department at Oxford is the largest in the western world, graduating
over 80 PhD scientists each year. The Department boasts a dozen
Fellows of the Royal Society, and has produced four Nobel Laureates.

About the Arizona Cancer Center
The Arizona Cancer Center's mission is to prevent and cure cancer
through excellence in patient care, research, and education. The
Center, directed by David S. Alberts, M.D., is one of a small,
prestigious network of comprehensive cancer centers designated by
the National Cancer Institute (NCI). Comprehensive status is the
highest ranking the NCI gives to cancer centers. This special
designation means that the center focuses not only on basic science
research and clinical (patient-oriented) research, but also on
prevention, control, and population sciences.

http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.mail-archive.com/biotech-news@yahoogroups.com/
http://www.mail-archive.com/biotech-news@yahoogroups.com/maillist.html

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Arizona receives a $4 Million American Indian Cancer Health Disparities Grant

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

Arizona receives a $4 Million American Indian Cancer Health
Disparities Grant from the National Cancer Institute (NCI)

10-25-2005

Phoenix, Arizona, September 25, 2005 – The National Cancer Institute
recently announced the award of $18 million to reduce cancer health
disparities through it's Community Networks to Reduce Cancer Health
Disparities through Education, Research and Training Program. The
Southwest American Indian Collaborative Network (SAICN) received one
of the 18-22 grants awarded nationwide. This network, which aims to
reduce cancer health disparities among American Indians, is a
collaborative effort lead by a core group of professionals from the
Inter Tribal Council of Arizona, Inc (ITCA), the Arizona Cancer
Center (AZCC), the Phoenix Indian Medical Center (PIMC), the
University of California at Los Angeles, the Translational Genomics
Research Institute (TGEN), and the Western Regional Community
Clinical Oncology Program (WRCCOP).
The collaboration was made possible, in part, through the
continuation of the Special Populations Network (SPN) grant "An
Innovative RFA for Minority Health Research and Minority
Advancement," also known as the American Indian Oncology Program.
Because of the work of all partners involved during the past four
years of SPN, a strong framework for collaborative partnership was
established. "This grant is a testament to what can be achieved when
programs work together for a common purpose," said Dr. Charlton
Wilson of the Phoenix Indian Medical Center.

"The fundamental aim of the Southwest American Indian Collaborative
Network (SAICN)," according to Dr. Kathryn Coe, the Principal
Investigator of the grant, "is to eliminate cancer health
disparities among American Indians in Arizona and the Southwest by
closing the gap between the health needs of the community and the
promise of cancer prevention and cure made possible through a
responsive health delivery and research system." This aim will be
achieved through support of participatory education, training, and
research programs driven by American Indian community needs. Cancer
is the second leading cause of death among American Indians. The
initial focus includes those cancers affecting American Indians in
the Southwest: breast, cervical, skin, lung, and colon.

"Participation in SAICN increases our effectiveness as a whole to
address cancer health disparity and expand resources. The hope is to
increase our ability to provide pertinent health programs through
our relationship with ITCA and a commitment by all partners to
include both urban and rural American Indians involvement at a
fundamental level," said Dr. David King, Medical Director of Western
Regional CCOP.

TGen is one of the new partners of this broadened network,
supplementing the research and training component, to ensure that
advances in molecular medicine and genomics are also integrated into
cancer treatment and prevention. "TGen is honored and excited to be
a part of this important Network," said Dr. Jeffrey Trent, President
and Scientific Director of TGen. "We look forward to working with
the network partners to ensure that the benefits of TGen's research,
specifically cancer therapeutics and diagnostics, are applicable and
accessible to American Indian cancer patients." Arizona, according
to Census 2000 summary data, retains its standing as the state with
the largest American Indian population residing on Indian lands.
Phoenix has one of the highest proportions of American Indians among
the top ten cities in the nation and Arizona is home to twenty-one
federally recognized tribes. Because of the rural nature of many
tribal communities, services commonly available to cancer patients
in urban areas are not available to American Indians in their
community settings. "This is a great opportunity for American
Indians to access the expertise and resources of partner agencies to
develop approaches to comprehensive cancer prevention and treatment"
said Mr. John R. Lewis, Executive Director of the Inter Tribal
Council of Arizona, Inc.

###

http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] InvestBio Ventures Invests $14 Million in The Vaccine Company

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

InvestBio Ventures Invests $14 Million in The Vaccine Company to
Initiate its Phase III Clinical Trial for the PR1 Vaccine for
Leukemia

InvestBio Ventures -- The Vaccine Company, L.P., an InvestBio
Ventures Partnership, announced today that it has raised $14 million
of a planned $20 million investment in The Vaccine Company (TVC).
This first stage of the investment in TVC was completed on October
17, 2005. InvestPrivate, Inc. acted as the placement agent for the
offering.

TVC was formed in July 2003 to commercialize the PR1 vaccine
that is being developed at the MD Anderson Cancer Center at The
University of Texas. The funding will help The Vaccine Company
initiate its pivotal Phase III clinical trial using the PR1 vaccine
to treat patients with acute myelogenous leukemia (AML).

On September 19, 2005, The Vaccine Company received approval
from the
Department of Health and Human Services to begin its clinical trial
in AML.
TVC is expected to begin the Phase III study in AML in the first
quarter of
2006. TVC also has announced plans to request approval to begin a
Phase II
clinical trial to treat MDS in the near future, pending completion
of the
Series C financing.
Said Scott Mathis, CEO and Chairman of InvestBio: "The Vaccine
Company is
a biotech company with significant potential. We're thrilled that
we were
able to help lead the effort to secure this financing. This is an
exciting
deal on many fronts and embodies our philosophy of 'Get Healthy, Get
Wealthy,'
helping the advancement of leukemia research for patients and
investors alike.
We and our investors in the InvestBio Ventures-The Vaccine Company,
L.P. fund
are very proud of helping finance the clinical trials of what may
be, if
successful, a breakthrough in leukemia treatment."
Ron Garren, M.D., Chairman and Founder of The Vaccine Company
stated, "We
are excited about the clinical potential of the PR1 vaccine and look
forward
to initiating the Phase III trial in AML."
InvestBio Ventures is an operation of InvestBio, Inc, an
organization that
seeks to help investors and its customers capitalize on business and
investment opportunities in the biotechnology sector.
InvestPrivate, Inc., a registered broker-dealer (member NASD,
SIPC, SIA),
under common control with InvestBio, Inc., served as the placement
agent in
connection with this investment.

About InvestPrivate:
InvestPrivate, Inc. (www.investprivate.com) (member NASD, SIPC,
SIA), founded in 1999 and headquartered in New York, is a boutique
investment
brokerage firm that specializes in the biotechnology sector,
offering access
to venture capital, private equity investments and publicly traded
securities.
InvestPrivate, Inc. is a holding of Diversified Biotech Holdings
Corp.
(DBHC), a diversified organization that seeks to help investors and
its
customers capitalize on business and investment opportunities in the
biotechnology sector.

About InvestBio:
InvestBio, Inc. (www.investbio.com) serves as a central resource
for biotech investors seeking unbiased information and access to
investment
opportunities. InvestBio, Inc. identifies, selects, structures and
manages
biotechnology-related venture capital, private equity and hedge fund
investments for qualified individual accredited investors.
InvestBio, Inc. is a holding of Diversified Biotech Holdings
Corp. (DBHC),
a diversified organization based in New York City that seeks to help
investors
and its customers capitalize on business and investment
opportunities in the
biotechnology sector.

Important Notes:
The Private Securities Litigation Reform Act of 1995 provides a
safe
harbor for forward-looking statements. This press release may
contain certain
statements of a forward-looking nature relating to future events or
future
business performance. Any such statements that refer to the Company's
estimated or anticipated future results or other non-historical
facts are
forward-looking and reflect the Company's current perspective of
existing
trends and information. These statements involve risks and
uncertainties that
cannot be predicted or quantified and, consequently, actual results
may differ
materially from those expressed or implied by such forward-looking
statements.
The forward-looking statements speak only as of the date of this
release. The
Company undertakes no obligation to update publicly any forward-
looking
statement, whether as a result of new information, future events or
otherwise.
For more information, please contact Scott L. Mathis, InvestBio,
Inc., at
(212) 739-7676 or info@investbio.com.

1999 - 2005. InvestBio, Inc., a subsidiary of Diversified
Biotech Holdings
Corporation. This information is not intended for use without
professional
advice.

SOURCE InvestPrivate/InvestBio

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
International Partners into Indian Biotech Firms
International Partners into Indian Biotech Firms


Although being on the ‘threshold of biotech revolution’. India has fallen behind Chinese and American companies in infrastructure and manufacturing. A market research report namely, Indian Biotech Industry Profile (2005) published by RNCOS, estimate this industry to reach $5 billion (Rs 22,000 crore) by 2010. However, the industry which, has developed competence in pharmaceuticals and drug development, fear loss of patent rights which can lead to discovery of generic drugs.



The Indian biotech industry confronts several challenges. First there is no increase in its budgets unlike in other major economies. Secondly, these activities could diminish the limited resources. And finally, in spite of high development of clinical activity, co-development would be the emphasizing factor.



India now seeks new partners with Chinese and European firms apart from the US. RNCOS’ market research report points out that the partnering in the biotech sector could alleviate poverty in India through effective medicine and improvements in agricultural and industrial productions. And, it discusses the success of biotech collaboration in terms of business, export and economic stability in the country.


Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Scottsdale Healthcare, TGen announce strategic alliance
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech

Scottsdale Healthcare, TGen announce strategic alliance

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/

Alliance brings translational medicine into the community

10-20-2005

SCOTTSDALE – Scottsdale Healthcare today announced a strategic
alliance with the Translational Genomics Research Institute (TGen)
in which Scottsdale Healthcare will become a primary clinical
research site for TGen.
Opening Oct. 24, the TGen Clinical Research Services (TCRS) will
include a Genomics Medicine and Individual Therapy Center and a
Pancreatic Cancer Center, and will be located in the Virginia G.
Piper Cancer Center at Scottsdale Healthcare. Additional clinical
research programs focused on other cancer types are planned in the
near future.

Daniel D. Von Hoff, MD, TGen's Senior Investigator and Director of
the Translational Drug Development Division will serve as medical
research leader of TCRS. As the new program grows it is expected to
move into a larger space in the Cancer Center's adjoining Research
Pavilion.

"The TGen-Scottsdale Healthcare alliance embodies our vision of
setting the standard for excellence in personalized healthcare,"
said Tom Sadvary, president & CEO. "The combination of world-class
researchers, community physicians and university faculty in the
Virginia G. Piper Cancer Center provides unprecedented access to new
therapies for the citizens of Arizona."

Valley residents will be among the first to benefit from new
treatments for disease. "The TCRS will bring new clinical research
into the community, and those patients who would otherwise have to
travel someplace else for access to new therapies or prevention
agents," said Dr. Von Hoff.

According to Dr. Von Hoff, the strategic alliance will allow
molecular and genomic discoveries made by TGen and others around the
world to reach the patient bedside as quickly as possible. Clinical
trials with agents directed at specific targets in patients' tumors
will be launched November 1, 2005. Phase I clinical trials of two
new cancer drugs will also be launched in November.

"We are seeing over 2300 newly diagnosed cancer patients each year
at Scottsdale Healthcare alone, and a number of these could benefit
from the research conducted through this new alliance," said Susan
Brown, associate vice president for oncology services at Scottsdale
Healthcare. Additional physician researchers are being recruited to
support TCRS, she said.

"We are honing in on the pathways to help tailor the right drug to
the right patient through molecular profiling," said Dr. Von
Hoff. "This new era of personalized genomic medicine offers the
ability to examine patients' tumors for molecular targets, and treat
those patients' tumors with more specialized therapeutics that have
potentially fewer side effects."

According to the National Institutes for Health, only 3% of adults
with cancer are participating in clinical trials. A recent study
shows that if given the opportunity and access to clinical trials,
63% of the population would participate, according to a survey by
the Charlton Research Co.

###

About Scottsdale Healthcare
Scottsdale Healthcare's vision is Setting the Standard for
Excellence in Personalized Healthcare. Established in 1962,
Scottsdale Healthcare is the not-for-profit parent organization of
the Scottsdale Healthcare Shea and Scottsdale Healthcare Osborn
hospitals, Virginia G. Piper Cancer Center, Scottsdale Healthcare
Thompson Peak medical campus, Scottsdale Clinical Research
Institute, Scottsdale Healthcare Home Health Services and Scottsdale
Healthcare Community Health Services. Based in Scottsdale, Arizona,
Scottsdale Healthcare is governed by a volunteer board of directors
composed of leading local citizens.

About TGen
The mission of the Translational Genomics Research Institute (TGen)
is to make and translate genomic discoveries into advances in human
health. Translational genomics research is a relatively new field
employing innovative advances arising from the Human Genome Project
and applying them to the development of diagnostics, prognostics and
therapies for cancer, neurological disorders, diabetes and other
complex diseases. TGen is focused on personalized medicine and plans
to accomplish its goals through robust and disease-focused research
programs and its state-of-the-art bioinformatics and computational
biology facilities.

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] TGen Awarded $15 Million to Discover and Develop New Therapies for Patients with
TGen Awarded $15 Million to Discover and Develop New Therapies for
Patients with Pancreatic Cancer

Grant focuses on bringing new technology to pancreatic cancer

10-20-2005

Phoenix, AZ, October 20, 2005-The Translational Genomics Research
Institute (TGen) has been awarded a five-year $15 million grant from
the National Cancer Institute (NCI) to lead a group of research
centers in the discovery and development of new therapies for
patients with pancreatic cancer.

This federally funded multi-center program project grant is the
first of its kind that focuses exclusively on pancreatic cancer. The
grant funds three projects with the key theme of accelerating the
delivery of new treatments for patients with pancreatic cancer, one
new compound for each year of the grant. Dr. Daniel D. Von Hoff will
serve as the principal investigator for the study.

"Our goal is to develop one successful candidate molecule for each
year of the grant that can be offered to patients in order to turn
the tables on pancreatic cancer," said Dr. Von Hoff, Director of
TGen's Translational Drug Development Division and the grant's
principal investigator. "Our approach is unique in that it focuses
on the development of innovative translational ways to tackle the
disease."

With a 96% mortality rate, pancreatic cancer is the deadliest of all
cancers. Approximately 35,000 people in the U.S. will be diagnosed
with pancreatic cancer this year and 31,800 people will die.
Pancreatic cancer does not discriminate by age, gender, or race, and
only 24 percent of patients will survive beyond one year. The five-
year survival rate is 4 percent. Despite the especially lethal
nature of pancreatic cancer, no effective early detection methods
have been developed, and there are very few effective treatment
options available to patients. At this time, the average life
expectancy after diagnosis with metastatic disease is just 3 to 6
months.

In addition to TGen, collaborators on the grant include the Arizona
Cancer Center at the University of Arizona and the University of
Texas M.D. Anderson Cancer Center. Together, this multidisciplinary
group combines their strength in drug development and the clinical
care of patients with new molecular targets and new genomic
technologies to bring renewed hope and innovative therapies to
patients with pancreatic cancer.

"The time to do this innovative research project is now. The
assembled group of investigators with experience at both the lab
bench and the patients' bedside are uniquely positioned to develop
new therapies and diagnostics for this devastating disease," said
Dr. Jeffrey Trent, TGen's President and Scientific Director.


The grant funds three translational research projects designed to
accelerate the development of new drugs for this devastating
disease.

The first project focuses on the environment in which the tumor
grows. Investigators know that pancreatic cancer tumors grow in a
low oxygen environment. Dr. Garth Powis of the University of Texas
M.D. Anderson Cancer Center is leading a team whose goal is to test
drugs in the clinic that will alter the micro-environment around a
tumor in order to prevent the tumor from growing.


"For the first time we have the necessary technology, the
infrastructure and the people to really make an impact on
discovering new molecules against pancreatic cancer," said Dr.
Powis. "We have exciting new drugs and we are starting right away to
test them in patients with pancreatic cancer."

The second project, headed up by TGen's Dr. Haiyong Han and Dr. Von
Hoff, leverages the knowledge that pancreatic cancer tumor cells
have deletions in their DNA. Together with their team, Dr. Han and
Dr. Von Hoff will identify potential candidate drugs that
selectively kill tumor cells that contain the deletions.

The third project, led by Dr. Trent and Dr. Spyro Mousses, Director
of TGen's Cancer Drug Development Laboratory (CDDL), uses genetic
manipulation to make pancreatic cancer tumor cells more sensitive to
drugs by applying a sophisticated technology called siRNA. The siRNA
technology allows researchers to figure out what in a tumor's DNA
can be used as an "Achilles Heel" to make drugs work more
effectively. Identifying these key points of vulnerability may also
lead to new targets, thereby giving researchers an earlier way to
detect the disease.

The grant is supported by four highly-integrated shared services,
including a tissue and blood bank, a computational center which will
facilitates information sharing and data analysis, an administrative
team, and a drug development strategy to accelerate safety testing
and speed the movement of potential drugs from the laboratory to the
clinic.

"The core services provide the infrastructure support needed to make
each project a success. By focusing on drug development and safety
testing, we can get these candidate molecules to the patients
faster," said the Arizona Cancer Center's Dr. Robert Dorr.

Pancreatic Cancer National Advisory Committee
The announcement of the grant coincides with today's inaugural
meeting of the National Pancreatic Cancer Committee, the first of
the TGen Foundation's National Advisory Councils chaired by U.S.
Senator John McCain. The National Pancreatic Cancer Committee is
chaired by pancreatic cancer survivor Howard Young of Atlanta, GA,
and is under the scientific leadership of TGen's Dr. Von Hoff, who
spoke at the meeting.

# # #

About TGen
The mission of the Translational Genomics Research Institute (TGen)
is to make and translate genomic discoveries into advances in human
health. Translational genomics research is a relatively new field
employing innovative advances arising from the Human Genome Project
and applying them to the development of diagnostics, prognostics and
therapies for cancer, neurological disorders, diabetes and other
complex diseases. TGen is focused on personalized medicine and plans
to accomplish its goals through robust and disease-focused research.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] MIT Enterprise Forum of New York City Presents Biotech Innovators

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

MIT Enterprise Forum of New York City Presents Biotech Innovators

WHO: The MIT Enterprise Forum of New York City presents Biotech
Innovators
-- NexGenix Pharmaceuticals, New York, NY
-- Chrono Therapeutics, Hamilton, NJ
-- Ideal Life, New York, NY

WHAT: NexGenix Pharmaceuticals, Chrono Therapeutics and Ideal Life
will discuss their organization's core business and
competencies, diverse customer base, market verticals served
and growth drivers, as well as the competitive landscape.

WHEN: Thursday, October 20, 2005
5:30 PM - 8:00 PM
Brown, Raysman Millstein & Steiner LLP
900 Third Avenue, New York, NY

For complete details and to register visit
web.memberclicks.com/mc/community/eventdetails.do?eventId=v669

About MIT Enterprise Forum of New York City

The MIT Enterprise Forum of NYC (MITEF) is a volunteer, not-for-
profit organization whose mission is to provide educational programs
and services that promote networking and innovation at the
intersection of business and technology. Formed by MIT alumni in
1971, MITEF has grown to 23 chapters worldwide. Membership and
program participation in MITEF events is open to all.

http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Wave Biotech Announces Strategic Alliance on Pandemic Influenza Vaccine Producti

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

Wave Biotech Announces Strategic Alliance on Pandemic Influenza
Vaccine Production Technologies

Wave Biotech, LLC, has announced today that the company is working
with a number of worldwide pharmaceutical and biotech manufacturers
that are making vaccines in the disposable Wave Bioreactor(R). In
its latest collaboration effort, Wave Biotech has entered into an
agreement with Novavax, Inc. (Nasdaq: NVAX), based in Malvern, PA,
and both companies will jointly collaborate on the development of a
commercial scale production process for Novavax's pandemic influenza
virus (avian flu) vaccine and other biological products. Wave
Biotech will provide process and equipment expertise for the
propriety technology based on disposable equipment for the
manufacture of biologicals. The initial focus of the collaboration
will be on Novavax's H5N1 avian-flu-Like Particle (VLP) vaccine. The
joint collaboration will demonstrate in a production process that
can express potent vaccine at high yield at the 500-liter scale.

Vijay Singh, President and founder of Wave Biotech, LLC, issued the
following statement: "Wave Biotech's disposable cell culture
technology is an ideal fit for the Novavax application because it
provides scalable technology that can be delivered, installed, and
commissioned quickly for possible worldwide use."

Non Traditional Approach May Prove Necessary in the Race Against
Time Wave Biotech first began development on their innovative
technology for the bioreactor six years ago, which may prove to be a
critical component in the race to develop vaccines before a flu
pandemic has an opportunity to occur. The company offers a quick way
to rapidly manufacture and deploy
bioreactors of up to 500 liters operating volume. Using large
plastic bags as
cell culture vessels, the bags are inflated, filled with culture
nutrients,
and inoculated with the cells of choice. These bags are placed on
special
machines that rock in a back and forth motion, generating waves that
effectively aerate and mix the contents, thus producing a highly
effective
environment for cell growth and productivity. The machines have been
fully
operational since 1999, and are currently in use at almost every
pharmaceutical or biotech company worldwide. They have been licensed
as part
of processes to produce human therapeutics and are built to comply
with all
applicable FDA guidelines. Most critically, they have a proven track
record
with many cell lines and viruses having been used for the production
of
proteins, viruses, gene therapy products, and vaccines. Due to the
inexpensive
and simple pre-sterilized disposable culture bag, cell culture can
be carried
out by low-tech labor without the need for extensive plant
infrastructure. The
rocking machines are mass-produced and can be delivered in weeks as
compared
to six months or longer for traditional stirred tank bioreactors.
Dr. Singh acknowledged that current issues concerning the
possibility of
an influenza pandemic striking humanity in the very near future is
based on
several notable factors. "First of all, the influenza virus is
capable of
mutating rapidly so that most people would have no significant
resistance and
would succumb. Additionally there is a disturbing increase in the
occurrence
of avian flu in Asia as well as the latest evidence in some of the
eastern
European countries. It is clear that the great influenza epidemic of
1918 was
avian origin, followed by others in 1957 and 1968," he
said. "Statistically,"
he continued, "another appears to be due at this time." He also
noted that
there are now anti-viral pharmaceuticals that may be useful in
treating those
people infected by the influenza virus, but he cautioned that the
efficacy and
availability of such drugs are very limited.
"The problem with influenza vaccines is that the virus mutates
rapidly and
a vaccine made against one strain will likely be useless against
another one,"
said Singh. "Making such a vaccine is very time consuming and takes
eight to
ten months to build up a significant stockpile of doses."
The manufacturing equipment developed by Wave Biotech can be
quickly
configured and deployed anywhere in the world within days. The cells
only
contact a single-use bag and these bags can be stockpiled for up to
three
years providing an option for almost instant vaccine manufacturing.
The
equipment has been optimized over several years to enable easy
operation with
minimal training required. This method would enable vaccine
facilities to be
rapidly established anywhere in the world to combat the disease at
the local
level, thus preventing its release into the general population. The
disposable
cell culture bags can be manufactured in large quantities in simple
factories
using heat seaming equipment, delivered pre-sterilized by radiation
and ready
for use.

Engineered Baculovirus
Current vaccine manufacturers use 1950's chicken egg technology
and other
methods to make the vaccine. Singh considers these methods far more
primitive
because "even 350 million chicken eggs would only yield 300 million
doses
which would take at least six months to develop." Dr. Singh
added, "This
technology is not likely to save a significant number of people since
compounding the problem is that if, indeed, the flu is avian origin,
then
where are the significantly large numbers of eggs needed to make the
vaccine
going to originate? The Spanish Flu epidemic of 1918 is estimated to
have
killed between 50 and 100 million people, at a time when world
population was
only 1.8 billion. Today we have 6.5 billion people and the impact of
a virus
such as the one in 1918 would clearly prove to be even more
devastating."
Singh claims it is both necessary and critical for governments
worldwide
to secure alternative technologies to rapidly make an engineered
cell line for
vaccine production.
"One approach, developed by Novavax, is to identify the gene
sequences of
the virus as it exists now in the Far East and rapidly clone into
baculovirus," said Dr. Singh. "This engineered baculovirus can be
used to
infect insect cells grown in liquid culture media and rapidly
express large
amounts of a suitable vaccine. This approach has been tested, proven
and
requires simple culture media that can be made from common
chemicals. This
way, it is possible to clone and develop a cell expressions system
against a
specific influenza strain within six weeks of securing the sample.
While
getting a cell line that produces the desired vaccine is only part
of the
story, in order to make sufficient quantities of the vaccine in such
a time-
sensitive manner, it will be essential to grow large numbers of
cells using
thousands of liters of cell culture capability."

About Wave Biotech
Wave Biotech is a research-based company that develops and
manufactures
innovative process equipment for the pharmaceutical and biotechnology
industries. The Company's focus is on developing disposable
bioprocess
equipment for the operation traditionally requiring stainless-steel
tanks and
piping. Key products, such as the Wave Bioreactor(R), WaveMixer(R),
FlexMixer(R), and Sterile Tube Fuser, feature disposable contact
materials
that eliminate cleaning and validation, thereby reducing costs in
operations
ranging from cell culture, media preparation, and buffer dissolution
and
thawing process intermediates to patient specific cell therapy in
hospitals.
These unique, patented, devices can be installed and commissioned
rapidly,
thereby drastically reducing the time-to-market for biological
products. Wave
Biotech's equipment is in use with hundreds of companies worldwide,
both for
R&D, as well as commercial applications.

SOURCE Wave Biotech, LLC

http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Oncolytics Biotech Inc. to Present at BIO InvestorForum in San Francisco: Financial News - Yahoo! Finance
Oncolytics Biotech Inc. to Present at BIO InvestorForum in San Francisco

Dr. Brad Thompson, Chairman, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview to institutional investors, pension fund managers, pharmaceutical and biotech corporate partners and other financial professionals at the BIO InvestorForum in San Francisco, on Thursday,

A live audio webcast of the presentation will be available at: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker(equal sign)W69590&item_id(equal sign)1147663 or www.oncolyticsbiotech.com. It is recommended that listeners log on 15 minutes in advance of the presentation to register and download any necessary software.

An audio replay of the presentation will begin one hour after the presentation time and will be available until October 26, 2005 at www.oncolyticsbiotech.com.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of REOLYSIN®, its proprietary formulation of the human reovirus, as a potential cancer therapeutic. Oncolytics' researchers have demonstrated that the reovirus is able to selectively kill human cancer cells in vitro that are derived from many types of cancer, including breast, bladder, prostate, pancreatic and brain tumours, and have also demonstrated successful cancer treatment results in a number of animal models. Phase I clinical trial results have indicated that REOLYSIN® was well tolerated and that the reovirus demonstrated activity in tumours injected with REOLYSIN®.

The webcast time is subject to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control and which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN® as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue reliance on forward looking statements. The Company does not undertake to update these forward looking statements.




--------------------------------------------------------------------------------
Source: Oncolytics Biotech Inc.
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
FLAVORx Wins Biotech Product of the Year -- A Company with Heart That Gives Back to Society
FLAVORx Wins Biotech Product of the Year -- A Company with Heart That Gives Back to Society

Of all the motivations for launching a business, love and fear may be the most powerful. This is why Kenny Kramm started FLAVORx the new Biotech Product of the Year. This is also what inspires him to tirelessly give back to society.


Kenny Kramm is CEO and President of FLAVORx (www.flavorx.com), winner of the Tech Council of Maryland’s 2005 BIO Product of the Year, for the conception, development and production of FLAVORx proprietary system and formulations. By manipulating medications, natural and artificial flavors, bitterness suppressors and sweetening enhancers, the FLAVORx Formularies change the acrid or foul-tasting chemical compounds being formulated as medications, into palatable pleasant-tasting liquids. The results for patients are significantly higher rates of medicinal compliance, shorter recuperative times and improved clinical outcomes. There are more than 30,000 participating pharmacies in the U.S. (including Walgreens, Wal Mart, CVS, Rite Aid, Target, Kmart, Albertsons, and Safeway to name a few). FLAVORx can also be found in Canada, Australia and New Zealand.



Kenny started the company out of love for his youngest daughter Hadley who was born with a seizure disorder and cerebral palsy. The medicine that was so crucial to her existence was intolerable to her and she would either spit it out or throw it up. His family was in the hospital repeatedly because Hadley was not getting the medication she so desperately needed and would start having seizures. He and his father owned a pharmacy and knew that flavoring medicine had been done for hundreds of years just never in any sort of systematic way. So they took Hadley's Phenobarbital and some concentrated candy flavorings and started to work with them to see if they could make the medicine palatable enough for her to swallow. They tried different concentrated flavorings, finally after several weeks they found that Hadley preferred banana flavor and although she didn’t love taking her medication she took it without complaint. This was the start of FLAVORx.

From that begining Kenny Kramm’s company met the challenge of bio-technically creating innovative solutions to medicinal flavorings. It is a testimony to Kramm’s skills, scientific savvy, and carefully crafted testing protocols, that with 50 million prescriptions having thus far been flavored, there has not been a single reported case of a medication not working, an adverse reaction or an allergic response; all human and veterinary flavors are FDA approved.

Kramm’s altruistic nature resulted in the development of the FLAVORx Research Institute, the R & D arm of the company, which works closely with pharmaceutical companies and numerous governmental agencies. While his latent entrepreneurial skills surfaced and became responsible for the founding and successes of the corporation, his experiences with his disabled daughter continue to motivate him to share his FLAVORx solution, pro bono, with others. His recent charitable successes include:

1. Turning ARV-HIV AIDS medication into a liquid form that is readily accepted by young children in stricken communities in Africa, Thailand and the Dominican Republic. Flavors, research and shipping are all done pro bono due to these extremely rural and indigent areas and populations.

2. FLAVORx-ing the water for a large U.S. Army division stationed in an area of Iraq where the water is potable, but has a particularly putrid taste. The troops, required to drink a minimum of one quart/hour to prevent dehydration in the 120° heat, were finding it almost impossible to do so because the water tasted so bad. Kramm produced a flavoring to mask the foul taste intrinsic to the water, allowing the soldiers to willingly drink it. Sending over thousands of bottles of flavoring with no charge, Kramm feels it is his civic duty.

3. Donating FLAVORx sets and flavors to the Katrina Relief Effort to help children who were sick, scared and alone. FLAVORx Systems and flavors were delivered to Ft. Gruber where many of the Katrina victims were brought.

Kenny Kramm recognizes that not all FLAVORx patients will completely improve, but he knows, from personal experience, that with good-tasting medications, an acute or chronically ill patient or pet can have the rocky road made a little smoother; the world a little kinder; and the ability to smile and laugh a bit easier.



Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Genentech Provides Information on Patent Reexamination
Biotech
Biotech


Genentech Provides Information on Patent Reexamination



SOUTH SAN FRANCISCO, Calif., September 28, 2005 Genentech, Inc. today provided information on the pending reexamination of the Cabilly, et al. U.S. Patent No. 6,331,415 ('415 patent), which was ordered by the U.S. Patent Office on July 7, 2005. Genentech had previously disclosed the existence of the reexamination in its Quarterly Report on Form 10-Q for the period ended June 30, 2005, filed with the Securities and Exchange Commission on August 2, 2005.



On September 13, 2005, the U.S. Patent Office issued an initial Office action rejecting the claims of the '415 or Cabilly patent. This action is a routine and expected next step in the reexamination procedure. Genentech plans to respond within 60 days from the mailing date of the action.

The Office action originates from a request for reexamination of the '415 or Cabilly patent filed on May 13, 2005 by a third party.

A final resolution of the reexamination may take from several months to several years. The Cabilly patent remains valid and enforceable while the reexamination is pending.

About Genentech

Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes multiple biotechnology products directly in the United States and licenses several additional products to other companies. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com .



Web site: http://www.gene.com//




Love Quotes Funny Quotes Love Quotes Recipes Recipes Arizona SEO Recipes Chicken Recipes Mantels Stone Mantels Gatlinburg Cabins Gatlinburg Cabins chicken recipes electromagnetic flowmeter Fireplaces Child Sexual Abuse Prevention Mantel Stone Mantel Cash Advances Fireplace Chicken Recipes Halloween Recipes Arizona Search Engine Optimization FREE Recipes Chicken Recipes Appetizer Recipes Appetizer Recipes Apple Recipes Apple Recipes Barbeque Recipes Barbeque Recipes Payday Loans Beef Recipes Beef Recipes electro magnetic flow meter Famous Quotes Famous Quotes Chicken Recipes Chicken Recipes Chicken Recipes Chicken Recipes Marketing Firms Chicken Recipes Chicken Recipes Chicken Recipes Payday Loans Chicken Recipes Stone Age Chicken Recipes Chicken Recipes Chicken Recipes Chicken Recipes Arizona Search Engine Optimization Chicken Recipes Chicken Recipes The Perception Of A Difference wireless lan
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] TGen and St. Joseph's Launch Pediatric Neurogenetics Center

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

TGen and St. Joseph's Launch Pediatric Neurogenetics Center

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/index.php

New clinic is 'last refuge' for children with neurological disorders

10-07-2005

Phoenix, AZ, October 7, 2005-The Translational Genomics Research
Institute (TGen) has teamed up with the Children's Health Center at
St. Joseph's Hospital and the Barrow Neurological Institute to
establish a new Pediatric Neurogenetics Center. The center will
provide a multidisciplinary diagnostic setting for children with
complex and tragic neurogenetic disorders.
"This clinic is a last refuge for children with neurological
disorders that remain unexplained. We will seek to use state-of-the-
art research tools to decipher diseases and offer solutions to
children and families," said Dr. Dietrich Stephan, head of TGen's
Neurogenomics Division. "This is a unique effort which complements
the significant expertise and focus in Arizona on keeping our
children safe and healthy."

The center's team of expert clinicians, researchers and academics
offers children and their families the most comprehensive care
available. The fusion of neurological, genetic and clinical
experience offered by the center's care team makes it the only
facility in Arizona and one of only a few in the nation to offer
this type of cutting-edge evaluation.

"Children with neurogenetic problems are often difficult to
diagnose," said Dr. Vinodh Narayanan, a pediatric neurologist at St.
Joe's. "They often go through extensive evaluations, exams, genetic
consultations, radiological studies, and genetic testing without
arriving at any conclusions."

The clinic is under the directorship of clinical geneticist Dr. Kirk
Aleck and Dr. Narayanan, who lead a staff of genetic counselors,
metabolic specialists, and highly trained nurse practitioners.

"We are dedicated to helping kids with complicated neurological
problems that may be genetic in origin and have been difficult to
diagnose. The collaboration between TGen, Barrow's, and St. Joseph's
Hospital creates a team that is unique and capable in making
progress in diagnosing these children."

The Pediatric Neurogentics Clinic is located on the campus of St.
Joseph's Hospital and Medical Center in Phoenix, AZ.

# # #

Media Contacts: Amy Erickson-TGen (602) 343-8522
Kimberly Lodge-St. Joseph's Hospital (602) 406-1050

About TGen
The mission of the Translational Genomics Research Institute (TGen)
is to make and translate genomic discoveries into advances in human
health. Translational genomics research is a relatively new field
employing innovative advances arising from the Human Genome Project
and applying them to the development of diagnostics, prognostics and
therapies for cancer, neurological disorders, diabetes and other
complex diseases. TGen is focused on personalized medicine and plans
to accomplish its goals through robust and disease-focused research
programs and its state-of-the-art bioinformatics and computational
biology facilities.

About St. Joseph's Medical Center
Located in the heart of Phoenix, Arizona, St. Joseph's Hospital and
Medical Center is a 520-bed, not-for-profit hospital that provides a
wide range of health, social and support services with special
advocacy for the poor and underserved. St. Joe's is a nationally
recognized center for quality tertiary care, medical education and
research. It includes the internationally known Barrow Neurological
Institute and the only Trauma Center in the state of Arizona that is
verified as a Level I Trauma Center by the American College of
Surgeons. The hospital is also a respected center for pediatrics,
maternity care, oncology, orthopedics, cardiology and many other
medical services.

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
INNOVIVE Pharmaceuticals Announces Scientific Advisory Board Members
INNOVIVE Pharmaceuticals Announces Scientific Advisory Board Members


INNOVIVE Pharmaceuticals, Inc., a biopharmaceutical company headquartered in Manhattan, announced today that three of the nation's leading cancer researchers have joined its Scientific Advisory Board.


"The expertise of these outstanding researchers will accelerate our development and ongoing acquisition of novel anti-cancer compounds," said Steven Kelly, President and Chief Executive Officer, INNOVIVE Pharmaceuticals, Inc.

The members of INNOVIVE's Scientific Advisory Board follow:

Peter Anthony Jones, Ph.D., Director of the USC/Norris Comprehensive Cancer Center, Distinguished Professor of Urology, Biochemistry and Molecular Biology, Keck School of Medicine at the University of Southern California and is currently President of the American Association for Cancer Research (AACR). Dr. Jones is a pioneer in the study of DNA methylation in human cancer, a process associated with controlling tumor suppressor genes in a wide variety of tumors.

Edward A. Sausville, M.D., Ph.D., Associate Director for Clinical Research, Greenbaum Cancer Center, University of Maryland. Dr. Sausville, who will be a non-compensated member of INNOVIVE's Scientific Advisory Board, has served as associate director of the National Cancer Institute's Developmental Therapeutics Program, which has played a key role in developing many currently used anti-cancer drugs. He was instrumental in bringing to clinical study, Velcade, the first of a new class of medicines approved for treatment of multiple myeloma.

Daniel D. Von Hoff, M.D., Senior Investigator and Head of Translational Research at the Translational Genomics Research Institute's Translational Drug Development Division and Head, Pancreatic Cancer Research Program in Phoenix, Arizona. He also is Chief Scientific Officer for US Oncology. Dr. Von Hoff and his colleagues were involved in the beginning of the development of many anti-cancer agents including mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, and CPT-11. He was appointed by the President to the National Cancer Advisory Board. He is past President of the American Association for Cancer Research, a founder of ILEX(TM) Oncology, Inc. (recently acquired by Genzyme), founder and the Editor Emeritus of Investigational New Drugs -- The Journal of New Anticancer Agents, and Editor-in-Chief of Molecular Cancer Therapeutics.

About INNOVIVE Pharmaceuticals

INNOVIVE Pharmaceuticals, Inc. is a privately held biopharmaceutical company headquartered in New York, N.Y. The company's mission is to acquire, develop and commercialize novel therapeutics addressing significant unmet medical needs in the fields of oncology and hematology. For additional information visit www.innovivepharma.com.

This press release contains forward-looking statements that involve risks and uncertainties that could cause INNOVIVE's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of INNOVIVE's development efforts relating to its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of INNOVIVE's product candidates, the risk that the results of clinical trials may not support INNOVIVE's claims, INNOVIVE's reliance on third party researchers to develop its product candidates and its lack of experience in developing pharmaceutical products. INNOVIVE assumes no obligation to update these forward-looking statements, except as required by law.


Recipes Famous Quotes
Columbus Day
Columbus Day
Columbus Stories - Holiday Stories - Stories for the Holidays
Famous Quotes recipes-famous-quotes-columbus-day
Christmas Day
Christmas Day Christmas Carols Christmas Carols
Christmas Stories - Holiday Stories - Stories for the Holidays
Bread Machine Chicken Recipes
Signs of Sexual Abuse in Children
Christmas Carol Harvest Festival
Recipes Christmas Recipe
Sales Training Famous Quotes Chicken Recipes for Chicken
Prevent Sexual Abuse Car Insurance Apple Recipes
Famous Recipes Spanish Recipes Chicken Recipes
Cooking Contests Inspirational Quotes Chicken Recipes
Chicken Recipes Funny Jokes Famous Quotes Recipes recipes-famous-quotes-columbus-day Kathee Sue KatheeSue recipes famous quotes columbus day


Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] W. L. Gore & Associates Acquires Premier Bioactive Heparin Technology Company

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

W. L. Gore & Associates Acquires Premier Bioactive Heparin
Technology Company

FLAGSTAFF, Ariz Oct. 5, 2005--W. L. Gore & Associates Inc. (Gore)
announced today that it has acquired Carmeda AB, a Sweden-based
manufacturer of the most clinically proven, hemocompatible surface
coating for medical devices. Carmeda has been a strategic supplier
to Gore of heparin and heparin-related technologies for nearly 10
years. Financial details and other terms of the agreement are
confidential. The Carmeda AB leadership team and work force will
remain in its existing facility in Upplands Vasby, Sweden.

The Carmeda(R) BioActive Surface (CBAS(R)) mimics the non-
thrombogenic properties of the endothelial lining of blood vessels
using a patented "end-point attachment" covalent bonding of heparin.
No other biologically active coating demonstrates the well-
documented long-term bioactivity of CBAS. The unique CBAS chemistry
enables the immobilized heparin on the device surface to reduce
thrombogenicity. Thus, CBAS expresses stable, antithrombotic
activity and avoids the "dosing" resulting from the leaching heparin
technologies.

Gore utilizes the CBAS coating in its GORE-TEX(R) PROPATEN Vascular
Graft. The CBAS coating provides unique hemocompatibility by
minimizing clot formation on the inside surface of GORE-TEX PROPATEN
Vascular Grafts. Such clots can result in blockages that can reduce
blood flow through the grafts and may require clinical intervention.
The GORE-TEX PROPATEN Vascular Graft is commercially available to
physicians in Europe and elsewhere outside the United States. It is
an investigational device in the United States, limited by U.S. law
to investigational use only. A U.S. clinical study under a Food &
Drug Administration (FDA) IDE is currently in progress.

John Sininger, leader of the Gore Medical Products Division,
stated, "At the heart of Gore's interest in Carmeda is our
comprehensive strategy for growing our business and expanding
offerings in the medical products marketplace. Part of that strategy
involves strategic acquisitions of companies that share our
commitment to applying product technologies that make a difference
in the lives of patients. Carmeda is just such a company."

"We are very excited at the prospects for the winning combination of
two premier biomedical technologies, bioactive heparin and ePTFE,
for improving medical device performance and positively impacting
patients' lives," said Paul Begovac, Ph.D., technology leader at
Gore. "We are confident that, together with Carmeda, we can continue
to offer our customers the finest and most innovative cardiovascular
products."

About Gore & Associates

The Gore Medical Products Division has provided creative therapeutic
solutions to complex medical problems for three decades. During that
time, more than 13 million innovative Gore Medical Devices have been
implanted, saving and improving the quality of lives worldwide. The
extensive Gore Medical family of products includes vascular grafts,
endovascular and interventional devices, surgical meshes for hernia
repair and sutures for use in vascular, cardiac, general surgery and
orthopedic procedures. Gore was recently named the second best
company to work for by Fortune Magazine. The company's Medical
Products Division is celebrating its 30-year anniversary worldwide
throughout 2005.

Products listed may not be available in all markets pending
regulatory clearance.

GORE, GORE-TEX(R) and PROPATEN are trademarks of W. L. Gore &
Associates Inc.

Carmeda(R) BioActive Surface and CBAS(R) are trademarks of Carmeda
AB.

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Herald.com | 10/06/2005 | Federal judge denies activists' Scripps plea
Herald.com | 10/06/2005 | Federal judge denies activists' Scripps plea

Herald.com | 10/06/2005 | Federal judge denies activists' Scripps plea


Federal judge denies activists' Scripps plea

A federal judge declines initial pleas from environmentalist groups to halt construction on the Scripps Research Institute.

BY JOHN PACENTI AND STACEY SINGER

Palm Beach Post


WEST PALM BEACH - Building a biotech village west of Palm Beach Gardens will ''eviscerate'' the state's growth management act by forever changing rural communities and wilderness, environmentalists argued Wednesday to an appellate court.

Opponents of placing a branch of California's Scripps Research Institute on a former citrus grove are looking for their second significant legal victory.

Last week, a federal judge said the U.S. Army Corps of Engineers erred by not performing an extensive environmental study of the entire project. On Wednesday, however, the judge, U.S. District Judge Donald Middlebrooks, denied environmentalists' request to stop construction until he considers further arguments.

The dispute revolves around whether the Palm Beach county commissioner's 2004 decision to change the land-use designation of the Scripps site -- called Mecca Farms -- to allow the massive biotech development violated state growth-management requirements.



http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] North Carolina Biotechnology Center to Dedicate New Offices in Wilmington, Green

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

North Carolina Biotechnology Center to Dedicate New Offices in
Wilmington, Greenville


RESEARCH TRIANGLE PARK, N.C., Oct. 5 -- The North Carolina
Biotechnology Center will formally dedicate new offices in
Wilmington and
Greenville on Oct. 10 and 11 as part of its Project to Strengthen
Biotechnology Across North Carolina. Both events are open to the
media.
The Southeastern Office in Wilmington will be dedicated Monday,
Oct. 10,
from 4 to 6 p.m. at the City Hall Council Chambers, 310 Chestnut St.
Speakers
will include Steve Troxler, commissioner of the N.C. Department of
Agriculture
and Consumer Services; Allen Meadors, chancellor of the University
of North
Carolina - Pembroke; Rosemary DePaolo, chancellor of the University
of North
Carolina - Wilmington; Fred Eshelman, chief executive officer of
PPD; and
Leslie Alexandre, president and chief executive officer of the
Biotechnology
Center.
The Eastern Office in Greenville will be dedicated Tuesday, Oct.
11, from
1 to 3 p.m. at the Rock Springs Center, 500 Aaron Circle. Speakers
will
include Norris Tolson, secretary of the N.C. Department of Revenue;
Mickey
Burnim, chancellor of Elizabeth City State University; Steve Ballard,
chancellor of East Carolina University; Kel Landis, senior advisor
to the
governor for business and economic affairs; and Leslie Alexandre,
president
and chief executive officer of the Biotechnology Center.
The Biotechnology Center is a private, non-profit corporation
supported by
the State of North Carolina. Its mission is to provide long-term
economic and
societal benefits to North Carolina by supporting biotechnology
research,
business and education statewide.

SOURCE North Carolina Biotechnology Center
Web Site: www.ncbiotech.org

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] TVM Raises $290.8 Million (EUR 240.3 Million) for TVM Life Science Ventures

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

TVM Raises $290.8 Million (EUR 240.3 Million) for TVM Life Science
Ventures VI; Fund to Focus on Biotech and Biopharmaceutical
Investment Opportunities in the U.S. and Europe
10/5/2005 6:00:00 AM EST

TVM, one of the leading life sciences and information technology
venture capital firms in Europe and the United States, today
announced the closing of its latest life sciences fund, TVM Life
Science Ventures VI (TVM LSV VI). Committed capital totaled $290.8
million (EUR 240.3 million) and was raised from a broad mix of
investors, including lead investors European Investment Fund (ERP-
EIF Fund of Funds) and AlpInvest. About 20 other investors from
Europe, the United States and Asia have invested in the new TVM
fund, including KfWBankengruppe (Germany), Skandia Liv Asset
Management (Sweden); Temasek Holdings Pte Ltd. (Singapore);
Development Fund, Taiwan government's economic investment catalyst;
and Quintiles Transnational Corp., the world's largest
pharmaceutical services organization. Genzyme Corporation, and
Biogen Idec, two of the most prominent global biotech companies
headquartered in the U.S., also invested in TVM LSV VI.

As with its previous funds, TVM LSV VI will maintain a strong
emphasis on investments in the fields of drug discovery and
development and will fund both early and late stage companies in the
U.S. and Europe. The percentage of early and late stage companies
will be market-driven, as TVM seeks to fund the best deals on both
continents.

The first two investments in the fund will be Newron Pharmaceuticals
SpA and elbion AG. Newron Pharmaceuticals is a Milan-based spin-out
of Pharmacia Upjohn, a late stage company engaged in the discovery
and development of innovative CNS compounds in the area of
neuroprotection, neurodegeneration and pain. Newron is currently in
phase III clinical development in Parkinson's Disease and in phase
II in neuropathic pain. elbion, located in Radebeul, Germany, is a
developer of small molecule therapeutics, and TVM is investing in
the company as part of the company's recently closed EUR 35 million
financing.

"The high quality of the investors in this fund is a testament to
TVM's strong track record of identifying promising life sciences
companies and supplying them with access to the scientific, capital
and management resources critical for success," said Dr. Helmut M.
Schuehsler, Managing Partner of TVM's Life Sciences practice. "One
of our strategic goals is to build a larger presence in the U.S.
biotech industry, as well as the emerging Asian market. Investments
from Biogen Idec, Genzyme, Quintiles and the first European
investment of Taiwan's Executive Yuan's Development Fund will help
us to intensify our access to the important U.S. biotech market and
to emerging markets in Asia."

While it is important to continue financing and developing existing
companies with advanced products to establish a top group of
successful and internationally competitive firms in this sector, TVM
also continues to see a great opportunity in early stage investing.
Currently, valuations for biotech firms are favorable for new
investors, enabling TVM to take a significant ownership position and
actively participate in the development of its portfolio companies.
As pharmaceutical giants increasingly look to biotechs to enhance
their product pipelines, effective value enhancements of start-up
companies with innovative products is becoming a more consistent
reality. TVM's four-to-seven year investment time horizon and active
participation in strategy and management gives its portfolio
companies the best chance to capitalize on this opportunity.

About TVM

TVM, founded in 1983, is one of the first venture capital firms
formed in Germany, and an early entrant into the U.S. market i